Prospective comparison of microbial culture and polymerase chain reaction in the diagnosis of corneal ulcer. by Kim, Elma et al.
Chidambaram, JD; Bird, M; Schiedler, V; Fry, AM; Porco, T; Bhatta,
RC; Jha, H; Chaudary, JS; Gaynor, B; Yi, E; Whitcher, JP; Osaki-
Holm, S; Lietman, TM (2004) Trachoma decline and widespread use
of antimicrobial drugs. Emerging infectious diseases, 10 (11). pp.
1895-9. ISSN 1080-6040
Downloaded from: http://researchonline.lshtm.ac.uk/834658/
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial No Derivatives
http://creativecommons.org/licenses/by-nc-nd/2.5/
Trachoma is disappearing in many parts of the world,
even in the absence of specific control programs. Following
mass antimicrobial drug treatments for trachoma in western
Nepal, the prevalence of trachoma declined far more rapid-
ly than could be attributed to the control program alone.
Pharmacy surveys in the same region found that children
received more antichlamydial drugs from sources outside
the trachoma program than they did from the program itself.
We demonstrate that high background antimicrobial drug
use may be responsible for much of the observed decline
in trachoma and discuss its potential role in eliminating this
infectious disease.
Trachoma is disappearing in many parts of the world,even in the absence of specific control programs. It is
a disease of the rural poor, and as living conditions have
improved during the last century, a corresponding decline
in trachoma has occurred (1–4). In Western Europe and the
United States, trachoma virtually disappeared by the late
20th century. Other infectious diseases such as syphilis,
chancroid, tuberculosis, and leprosy also began to subside
in Europe and the United States during this time. This
downward trend seems to have begun before, and contin-
ued into, the antimicrobial drug age. Therefore, many
attribute this decline to socioeconomic factors, such as
improved sanitation and social changes, and even to legis-
lation to control venereal disease, rather than to antimicro-
bial drugs. Addressing the importance of antimicrobial
agents in the disappearance of these infectious diseases ret-
rospectively is difficult. In the case of trachoma, we have
a unique opportunity to observe the effect of rising antimi-
crobial pressure in the community on a disease that is in
decline but has not yet disappeared. 
From 1998 to 2001, a region of western Nepal was
monitored for trachoma prevalence, following mass
antimicrobial drug distribution for trachoma. A dramatic
fall in disease prevalence was observed that could not be
attributed to the effect of the trachoma control program
alone (5). We conducted a survey of pharmacies in the
same region and found a surprisingly large quantity of
antimicrobial drugs were being used for indications other
than trachoma control (6). Here, we evaluate whether this
background antimicrobial use may be responsible for the
downward secular trend in the prevalence of trachoma. 
Analysis of Decline in Trachoma 
Prevalence in Western Nepal
From May 1998 to May 2001, a total of 25 villages
from three subdistricts (known as Village Development
Committees) in the Kailali and Konchapur districts of far-
western Nepal were monitored for clinically active tra-
choma. During this time, an annual mass azithromycin
treatment program began. At each visit, all children 1–10
years of age were examined for signs of clinically active
trachoma by using the World Health Organization (7) sim-
plified trachoma grading system (8). In total, >20,000
examinations were performed; 180–650 children were
examined during each village visit (5). The presence of a
secular trend, a downward trend independent of the
trachoma program, was evaluated by monitoring one third
of the villages for 6 months before any antimicrobial drug
treatment was given. Seasonal variation was determined
by performing village visits in both the spring and the fall.
No other specific trachoma prevention activities such as
hygiene, fly control, or water supply programs were insti-
tuted during the course of this study (9).
Trachoma prevalence data were analyzed by using a
multivariate autoregression (AR1) model with the follow-
ing covariates: effect of the trachoma program, seasonal
variation, and secular trend. The analysis showed that the
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trachoma program’s distributions of antimicrobial drugs
alone could account for some, but not all, of the observed
reduction in clinically active trachoma (5). A substantial
proportion of the decrease in trachoma prevalence 6
months posttreatment was attributable to a secular trend,
independent of the trachoma program’s effect and season-
al changes (26% decrease, p < 0.001, 95% confidence
interval [CI] 15%–35% decrease).
Antimicrobial Pressure from 
Outside the Trachoma Program
From February to May 2000, all pharmacies and gov-
ernment health posts in the Geta subdistrict of Kailali were
surveyed to establish the total quantity of antimicrobial
drugs distributed. All of these will be called pharmacies for
the purposes of this article. Information obtained included
the number of years each medicine hall had been open and,
for each patient, age, antimicrobial agent, amount distrib-
uted, and patient’s village. Pharmacy purchase receipts
from this time period were also collected for analysis. The
survey was repeated in September 2001 to gain additional
patient information and to ensure that no gross seasonal
variations occurred (6). 
We analyzed these data to determine what percentage
of the total antimicrobial agents distributed had antich-
lamydial activity. Susceptibility testing suggested that
trimethoprim-sulfonamide combinations, tetracycline,
macrolides, chloramphenicol, and amoxicillin are all effec-
tive against chlamydia. Also, other penicillins,
cephalosporins, and the fluoroquinolones (ciprofloxacin
and norfloxacin) are less effective antichlamydial agents
(10). However, susceptibility testing for chlamydia has
been difficult to standardize (11), and alternative assump-
tions could alter these percentages somewhat. For exam-
ple, including ciprofloxacin, which has some effect against
Chlamydia trachomatis, would have increased the propor-
tion effective against chlamydia by 12%, but we used the
lower, more conservative figure for analysis. To facilitate
direct comparison of different antimicrobial agents, the
total amount of antichlamydial antimicrobial drugs was
converted into the standardized unit of defined daily doses
(DDD). DDD is defined as the assumed average mainte-
nance dose per day for a drug used for its main indication
in adults (12). For children, the number of prescriptions
given per child per year was calculated with 1998 census
data. Both DDDs and the prescriptions per person-year are
convenient measures to compare antimicrobial pressure,
although neither is ideal; DDDs do not take into account
the duration of each drug’s antichlamydial activity, and
prescriptions are not for a uniform amount of medication.
We estimated that pharmacies in Geta distributed 3.0
DDD of antimicrobial drugs per person per year in 2000
(Table). Sixty-eight percent of these prescriptions were
effective against chlamydia (Figure 1). Thus, pharmacies
distributed 2.0 DDD per person per year of antichlamydial
agents. Forty-nine percent of all antimicrobial agents were
distributed to children 0–10 years of age, and 33% to pre-
school children 0–5 years of age. We estimated that on
average 1.2 prescriptions of antichlamydial agent are given
to each preschool child per year (Table).
The number of pharmacies in Geta subdistrict has
increased from 2 to 14 within the last 20 years, coinciding
with the decrease in trachoma prevalence in the Tarai
region of Nepal (Figure 2) (2). Eight of these pharmacies
(57%) have been open for <5 years, and 10 (71%) for <10
years. In the last 20 years, the number of pharmacies has
increased sevenfold, while the population of Geta has
grown by approximately twofold, which suggests that
more than three times as many pharmacies exist per person
currently than in 1980.
Antimicrobial Drug Use 
within the Trachoma Program
The trachoma control program in Kailali and Konchapur
distributed single-dose oral azithromycin annually, as per
World Health Organization (WHO) guidelines and covered
an estimated 80% of the targeted population with its antimi-
crobial treatments (5,9). One gram of azithromycin is the
recommended single dose in an adult to treat ocular
chlamydial infection. This dose is equivalent to 3.3
DDD/person (12). For children, the recommended single
dose of azithromycin is 20 mg/kg. The average dose for all
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ages (adults and children) was found to be approximately
2.3 DDD/person (9). With a treatment coverage of 80% of
the entire population as recommended by WHO, a tra-
choma program would therefore administer 1.8 DDD/per-
son at each mass distribution of antimicrobial agents. 
Antimicrobial Drug Use Necessary for
Elimination of Trachoma in Western Nepal
Using a previously described mathematical model, we
estimated the frequency of mass azithromycin distribu-
tions and the amount of antimicrobial drug needed to
eliminate infection from this region of western Nepal (13).
Before treatment, the average prevalence of active tra-
choma was 17% in children 1–10 years of age in western
Nepal (5). With antimicrobial drug treatment that is 95%
effective in a person and with 80% coverage of the popu-
lation, the model indicates that mass treatments would be
needed every 1.7 years (20.4 months) in western Nepal to
progressively reduce the prevalence of active trachoma.
Therefore, mass treatments given annually would be more
than enough to eliminate ocular chlamydial infection. 
Discussion
The amount of antichlamydial drugs given out by phar-
macies in Geta (2.0 DDD/person/year) is slightly more
than the estimated amount that would bring about the elim-
ination of ocular chlamydial infection in this region of
western Nepal (1.9 DDD/person/year). Children, in partic-
ular preschool children, are by far the most likely to harbor
ocular chlamydia. Pharmacies distributed nearly one half
of the total antimicrobial agents to children 0–10 years of
age, and one third to children 0–5 years of age. Preschool
children received 1.2 prescriptions per year of antimicro-
bial drugs that are effective against chlamydia, which is far
more than the estimated 0.6 per year that would eliminate
infection. We therefore conclude that antibiotics given for
reasons other than trachoma control may play a role in the
disappearance of trachoma in this region.  
The prevalence of active trachoma has decreased in
many regions of the world in the absence of programs
specifically targeting this disease (1–4,14,15). From 1981
to 1996, active trachoma in children declined from 30% to
<10% in each of two adjacent districts of western Nepal;
one district had an intense trachoma control program; the
other district did not (2). Surveys in the Kailali and
Konchapur districts of western Nepal have shown a large
secular trend, suggesting that active trachoma would have
disappeared rapidly even if a trachoma program had not
been implemented (5). This situation is not unique to
Nepal. A village in Gambia had hyperendemic trachoma in
1959 (66% prevalence in children), yet a followup survey
in 1987 found that active disease had nearly disappeared,
after only a modest 2-year control program of tetracycline
administration (1). A study in Malawi showed a 50%
reduction in active trachoma over a 16-year period in the
absence of a specific trachoma program (4). 
What might be the cause of this secular trend seen in so
many countries? Various socioeconomic factors have been
associated with the disappearance of trachoma, but studies
have had difficulty establishing causality for any of them
(16–18). In particular, facial hygiene and fly density are
both believed to be related to trachoma activity (19–21).
Several studies have associated dirty faces with active tra-
choma (22,23), but a trial involving intensive face-wash-
ing produced a modest (and statistically insignificant)
decrease in clinically active trachoma at 1 year (21). The
face fly (Musca sorbens) has been implicated as a vector
of trachoma (24,25). A recent study in the Gambia found
that regular insecticide spraying in villages did reduce
active trachoma (25); however, future controlled studies
are necessary to determine the sustainability of this prom-
ising measure.
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Figure 1. Antimicrobial drug use in Geta, Nepal. Antimicrobial drug
sales in a 3-month period (mid-February to mid-May 2000) from all
pharmacies in the Geta subdistrict, expressed as defined daily
doses (DDDs) and as a percentage of the total DDDs sold (6). The
shaded region represents antimicrobial drugs that are effective
against Chylmydia trachomatis.
Figure 2. Number of pharmacies in Geta, Nepal. The number of
pharmacies in Geta subdistrict increased from 2 in 1980 to 14 in
2001.
What role have antimicrobial agents played in the dis-
appearance of trachoma? In a person, ocular chlamydial
infection can be successfully treated with a single dose of
azithromycin (26,27). At the community level, controlled
trials in Tanzania, Gambia, and Egypt have shown that a
single course of azithromycin can markedly reduce ocular
chlamydial infection, even 1 year later (28). Our findings
in this study support the hypothesis that the rising use of
antimicrobial drugs in the community for indications other
than trachoma may contribute to the disappearance of this
disease. 
Several of the principal antimicrobial drugs used in
Nepal for systemic infectious diseases have antichlamydi-
al action. National treatment guidelines for childhood
pneumonia recommend co-trimoxazole (a combined
preparation of sulfonamide and trimethoprim) as the treat-
ment of choice, followed by amoxicillin or oral chloram-
phenicol as second-line therapy (29). Other childhood
infectious diseases are treated according to the adapted
WHO Integrated Management of Childhood Illness (30).
WHO recommends chloroquine as the first-line therapy
for malaria in Nepal, and sulfadoxine-pyrimethamine for
chloroquine-resistant cases (31). The latter drug has
antichlamydial activity through its sulfonamide compo-
nent, sulfadoxine. 
Why trachoma is disappearing should be investigated
before it is gone, so that this knowledge can be applied to
other diseases. If infection in a region is already in decline,
the effect attributed to a trachoma control program may be
exaggerated, and the program’s success may not be dupli-
cated in less fortunate areas. Conversely, beneficial factors
could be introduced in areas where a downward secular
trend does not already exist. Much discussion has taken
place about the dangers associated with the indiscriminate
use of antimicrobial drugs. These problems should be bal-
anced against the benefits. The widespread use of antimi-
crobial drugs in developing countries for indications other
than trachoma may play a role in eradicating one of the
world’s leading causes of preventable blindness. 
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